REGN · Regeneron Pharmaceuticals

S&P 500 #192 · NASDAQ-100 #50 · Nasdaq

Risiko 5/10 · Pharma Value with Pipeline Overhang · $695.18 ▲ 4.20%

Kennzahlen

• Price $695.18
• Market cap $72.9B
• P/E (ttm) 16.97
• Div yield 0.56%
• 52-wk range $541.00 – $821.11
• Index rank #192 / #50

Wichtigste Risiken

• Dupixent Patent / Biosimilar Exposure (Long-term holders) — HIGH
• Drug Pricing / IRA Policy Risk (All investors) — HIGH
• Pipeline Clinical Trial Failures (Speculative investors) — MED
• Down 23% from 52-week High (Momentum investors) — MED

Fazit

Regeneron is attractively valued at 15x earnings with Dupixent still growing, but trades 23% below its 52-week high amid biosimilar timing uncertainty and drug pricing reform headwinds.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.